Home › Hypertrophic Cardiomyopathy › Missouri
Hypertrophic Cardiomyopathy clinical trials in Missouri
3 studies for Hypertrophic Cardiomyopathy are looking for participants at sites in Missouri.
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- St. Luke's Mid-America Heart Institute, Kansas City
- Washington University, St Louis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05489705Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
- St. Luke's Hospital - Mid America Heart Institute, Kansas City
RecruitingPhase 4
Ages 18 to 90 · All sexes · Updated May 20, 2026 · NCT07600177A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Imbria Investigational Site, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT07023614From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.